SanthoshKKoshyMD
Cardiology • Kalamazoo, MIAdult Congenital Heart Disease, Cardiac Electrophysiology, Interventional Cardiology
Associate Professor, Medicine, University of Tennessee, Memphis, College of Medicine
Dr. Koshy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1722 Shaffer St
Ste 1
Kalamazoo, MI 49048Phone+1 269-381-3963
Education & Training
University of Alabama Medical CenterFellowship, Interventional Cardiology, 2004 - 2005
University of Missouri-ColumbiaFellowship, Cardiovascular Disease, 2000 - 2003
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 1997 - 2000
University of Kerala Medical CollegeClass of 1991
Certifications & Licensure
GA State Medical License Current
MI State Medical License 2022 - 2028
MO State Medical License 2001 - 2026
TN State Medical License 2008 - 2025
TX State Medical License 2006 - 2025
FL State Medical License 2003 - 2023
AZ State Medical License 2007 - 2009
American Board of Internal Medicine Cardiovascular Disease- American Board of Internal Medicine Interventional Cardiology
- Join now to see all
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- Comparative Effectiveness of On-Pump Versus Off-Pump Coronary Surgical Revascularization Related to Postoperative Acute Kidney Injury.Santhosh K G Koshy, Ajit K Tharakan, Lekha K George, Gregory F Petroski, Martin H Gregory
The American Journal of Cardiology. 2025-03-01 - Pus in the Pericardium: A Pericardial-Oesophageal Fistula with Cardiac Tamponade after Ablation for Atrial Fibrillation.Taha Mansoor, Nahal Massoudi, Anandbir Bath, Matthew Kelly, Santhosh Koshy
European Journal of Case Reports in Internal Medicine. 2025-01-01 - Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future.Taha Mansoor, Bassam Hamid Rao, Kartik Gupta, Sachin S Parikh, Dmitry Abramov
American Journal of Cardiovascular Drugs. 2024-12-20
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
